Eir Ventures

Today, we have announced the appointment of Ben Machielse to Scenic’s Board of Directors. Ben brings over 25 years of drug development expertise, covering all stages from preclinical evaluation to commercialization, from life science companies, including Sucampo Pharmaceuticals-acquired Vtesse and AstraZeneca-acquired Omthera Pharmaceuticals. We welcome Ben to our board and look forward to having his drug development expertise for rare diseases as we accelerate our pipeline of innovative modifier therapies toward the clinic. Read the full press release to find out more about this announcement: https://lnkd.in/dN8WZt6a

We are so happy to share that we have received funding from BIO-X Accelerate💥. With the support from the call that focus 🎯in on IMPACT we will pursue our work on the Adaptable Drug Affinity Conjugate (ADAC) technology💊, to provide a technology for targeted delivery of oligonucleotide-based therapies! Together with our collaborators Jonas Nilsson Tommy Lidström Ulf Tedebark OLIGOMED - Oligonucleotides for Medical Applications and our investors we can ramp up our efforts 👊🎉 STUNS Life science European Regional Development Fund Tillvaxtverket Eir Ventures Flerie Uppsala universitet Invest AB Olle Wahlqvist Almi Invest SLU Holding AB https://lnkd.in/dgxZ2wKv About BIO-X BIO-X Accelerate is a program with the goal of accelerating the development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfill well-defined needs and create IMPACT in healthcare, industry and society. Selected companies receive funding for their projects as well as continued support and access to experts within the BIO-X network. BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding. The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS. About STUNS STUNS is the foundation for collaboration between the universities in Uppsala, business and society. STUNS Life science is a strategic hub for collaboration between private and public actors to contribute to sustainable knowledge-based growth - in life science, health and neighboring disciplines.

🙌 🏆 INGE MARIE SVANE MODTAGER KIRSTEN OG FREDDY JOHANSENS LÆGEVIDENSKABELIGE KLINISKE FORSKERPRIS 2024🏆 🙌 I fredags modtog Inge Marie Svane den prestigefyldte Kirsten og Freddy Johansens Lægevidenskabelige Kliniske Forskerpris. Prisen på 1,75 mio. kr., hvoraf 250.000 kr. er en personlig hæder, blev tildelt Inge Marie Svane, på grund af hendes enestående bidrag og forskningsindsats på højeste internationale niveau. Prisoverrækkelsen blev fejret ved en frokost i Festsalen på Frue Plads. Stort tillykke 🎉 Københavns Universitet - University of Copenhagen Region Hovedstaden CCIT - Center for Cancer Immune Therapy, Denmark Afdeling for Kræftbehandling, Herlev og Gentofte Hospital

We are happy to announce the successful completion of our Phase II study for Supernitro! For more detailed information, please read our official press release.

Enjoy our new website

What an impressive presentation from Inge Marie Svane, MD, PhD, “State-of-the-Art Advancements on Cancer Vaccines and Biomarkers” at #ASCO2024. #TargetedOncology #ClinicalDevelopment #ASCO